NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hoffmann-La Roche
Conditions: Coronary Heart Disease
Interventions: Dalcetrapib (RO4607381), Placebo
Countries: United States, Canada
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre-randomisation period during which positron emission tomography computed tomography (PET/CT) and MRI will be conducted, patients will be randomized to receive either RO4607381 600mg po daily, or placebo po daily. PET/CT and MRI scans will be taken at intervals during the study. The anticipated time on study treatment is 2 years, and the target sample size is 100 individuals.
Sex: ALL
Age: 18 Years to 75 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * adult patients, 18-75 years of age; * CHD, including patients with other CHD risk factors; * treated appropriately for dyslipidemia; * clinically stable. Exclusion Criteria: * previous exposure to any cholesteryl ester transfer protein (CETP) inhibitor or vaccine; * recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident; * severe anemia; * uncontrolled hypertension; * poorly controlled diabetes.
- Jacksonville, Florida, United States
- Royal Oak, Michigan, United States
- Minneapolis, Minnesota, United States
- Kansas City, Missouri, United States
- New York, New York, United States
- Statesville, North Carolina, United States
- Cincinnati, Ohio, United States
- Cincinnati, Ohio, United States
- Cleveland, Ohio, United States
- Houston, Texas, United States
- Seattle, Washington, United States
- Montreal, Quebec, Canada